Equities research analysts expect Seres Therapeutics Inc (NASDAQ:MCRB) to post earnings per share of ($0.26) for the current quarter, according to Zacks. Three analysts have issued estimates for Seres Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.30). Seres Therapeutics posted earnings of ($0.52) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 50%. The firm is expected to issue its next quarterly earnings results on Wednesday, March 4th.
According to Zacks, analysts expect that Seres Therapeutics will report full year earnings of ($1.42) per share for the current year, with EPS estimates ranging from ($2.04) to ($1.20). For the next year, analysts expect that the business will post earnings of ($0.87) per share, with EPS estimates ranging from ($1.26) to ($0.51). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03. The firm had revenue of $7.03 million during the quarter, compared to analyst estimates of $6.69 million.
Several analysts recently issued reports on MCRB shares. Zacks Investment Research downgraded Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Seres Therapeutics in a research report on Thursday, November 21st. Cowen reissued a “buy” rating on shares of Seres Therapeutics in a research report on Monday, November 4th. Chardan Capital restated a “buy” rating on shares of Seres Therapeutics in a report on Thursday, September 19th. Finally, BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Seres Therapeutics currently has an average rating of “Buy” and an average price target of $7.75.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its stake in Seres Therapeutics by 3,656.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,678 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 8,447 shares during the last quarter. Aries Wealth Management purchased a new stake in shares of Seres Therapeutics during the 3rd quarter worth approximately $31,000. SG Americas Securities LLC purchased a new stake in shares of Seres Therapeutics during the 2nd quarter worth approximately $34,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Seres Therapeutics in the 2nd quarter worth approximately $42,000. Finally, Voya Investment Management LLC grew its holdings in shares of Seres Therapeutics by 35.1% in the 3rd quarter. Voya Investment Management LLC now owns 13,670 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 3,555 shares during the period. Hedge funds and other institutional investors own 91.91% of the company’s stock.
Shares of NASDAQ MCRB traded down $0.10 during mid-day trading on Wednesday, hitting $3.65. The company had a trading volume of 2,972 shares, compared to its average volume of 182,598. The firm has a 50-day simple moving average of $3.67 and a two-hundred day simple moving average of $3.39. The company has a market capitalization of $276.55 million, a PE ratio of -1.51 and a beta of 1.82. Seres Therapeutics has a one year low of $2.02 and a one year high of $8.39.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Recommended Story: What factors cause inflation to rise?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.